About Contact Us Careers

Hemophilia A Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2422
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Hemophilia A Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd
Novo Nordisk A/S
Genzyme Corporation
Grifols, S.A.
CSL Behring
Octapharma AG
Aptevo Therapeutics
Ferring Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Hemophilia A Treatment Market Size & Share, Growth Report 2037

In the News

On April 1, 2020, the U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw], a drug containing a recombinant analog of human FVII as the active ingredient, for the treatment as well as control of bleeding in people above the age of 12 with hemophilia A or B.

Author Credits: Radhika Pawar

Report ID: 2422
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

North America industry is poised to account for largest revenue share by 2037, attributed to recent advancements in the healthcare industry as well as the research and development of new drugs.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.

Inquiry Before Buying Request Free Sample